The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...
But when the researchers analyzed the data, they found that fluoxetine appeared not to provide meaningful benefits for ...
The FDA has granted 510(k) clearance and a label expansion for a transcranial magnetic stimulation device to treat patients ...
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on ...
MedPage Today on MSN
FDA Broadens Caplyta Approval to Include Major Depression
The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults, Johnson & Johnson announced. Lumateperone was previously ...
Another of the psychiatry drugs Neurocrine Biosciences licensed from Takeda has stumbled in the clinic. | Another of the ...
BrainsWay announced today that the FDA granted a label expansion for its deep transcranial magnetic stimulation (Deep TMS) ...
The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression - making it the first FDA-approved oral pill in the United States specifically for ...
SAN FRANCISCO, California -- For the first time, the FDA has approved a medication specifically to treat new mothers who suffer from postpartum depression. The drug is called Brexanolone and will be ...
Postpartum depression descended on Kristina Leos like a heavy fog that separated her from everyone she loved. She could see ...
The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback